Calcineurin (CN) influences myosin phosphorylation and alters endothelial barrier function; however, the molecular mechanism is still obscure. Here we examine whether CN controls myosin phosphorylation via mediating the phosphorylation state of Thr696 in myosin phosphatase (MP) target subunit 1 (MYPT1), the phosphorylation site inhibitory to the catalytic activity of MP. --
Introduction
An important function of vascular endothelial cells (ECs) is to maintain a selective barrier, thereby controlling the exchange of molecules and cells across the wall of blood vessels. 1 Physiological and/or pathological stimuli (e.g. inflammation, allergy, physical injury) may change the integrity of ECs, leading to the formation of gaps between the cells, thus compromising barrier function and increasing vessel permeability. The cytoskeletal and intercellular junction proteins of ECs play an important role in the regulation of barrier integrity, and their physiological functions are often mediated by phosphorylation on Ser/Thr/Tyr residues. 2, 3 These findings directed our attention to uncover the types of protein kinases and phosphatases implicated in the phosphorylation of key endothelial proteins involved in the mediation of endothelial permeability. 4 Actomyosin-based contractility of ECs is involved in the regulation of cell shape and stress fibre formation, which are major factors in the development of intercellular gaps during decreased barrier integrity. 5 The contraction of ECs is elicited by increase in intracellular Ca 2+ [Ca 2+ ] i and in the phosphorylation of the 20 kDa regulatory light chain of non-muscle myosin II (MLC20). The latter is balanced by the actual activity ratio of MLC20 kinases (MLCKs) and myosin phosphatase (MP). 6 MP consists of the d isoform of protein phosphatase-1 (PP1) catalytic subunit (PP1cd), PP1cd-associated 130-133 kDa regulatory protein termed myosin phosphatase target subunit 1 (MYPT1), and a 20 kDa protein bound to the C-terminal region of MYPT1. 7 It is regulated via the RhoA/RhoA-activated kinase (ROK) pathway since ROK phosphorylates Thr696 and Thr853 in MYPT1, resulting in the inhibition of phosphatase activity. 8, 9 MP inhibition could also occur by a 17 kDa protein termed CPI-17, which is activated via phosphorylation at Thr38 by protein kinase C or ROK. 10 CPI-17 is expressed in ECs and involved in histamine-and thrombin-induced barrier dysfunction 11 as well as in antagonizing thrombin-induced MP inactivation by cAMP/PKA. 12 The level of phosphorylated MYPT1-Thr696 (MYPT1 pThr696 ) reflects the activity status of MP and it is correlated with the extent of MLC20 phosphorylation and the changes in endothelial permeability. 13 -15 Thus, uncovering the physiological regulation of the phosphorylation status of MYPT1 may significantly contribute to understanding these processes. The kinases that phosphorylate MYPT1 at Thr696 are quite well characterized, whereas the phosphatases involved in dephosphorylation are much less understood. Protein phosphatase-2A (PP2A) and the Ca 2+ -calmodulin (CaM)-dependent protein phosphatase, termed calcineurin (CN) or protein phosphatase-2B (PP2B), were considered as potential MYPT1 phosphatases acting on MYPT1 pThr696 and MYPT1 pThr853 as revealed by in vitro assays. 16 CN/PP2B has been implicated in the mediation of both myosin phosphorylation 17 and endothelial permeability 18 ; however, its cellular targets are not unambiguously identified yet.
We showed recently that CN contributed to the recovery of ECs from thrombin-induced barrier dysfunction, whereas pharmacological inhibition of CN by cyclosporin A (CsA) or FK506 prolonged the contractile effect and maintained gap formation between ECs. 19 The goals of the present study were to dissect the molecular mechanism by which CN may affect the contractile machinery, with special interest in the mediation of MLC20 phosphorylation by the regulation of MP. Our present data suggest that CN is directly involved in the dephosphorylation of MYPT1 at both MYPT1 pThr696 and MYPT1 pThr853 , and it influences the phosphorylation level of cofilin too. It is concluded that CN mediates MLC20 phosphorylation via the regulation of MP and actin filament reorganization with a concomitant effect on endothelial permeability. Moreover, dephosphorylated MYPT1 and CN form a stable interaction which may have physiological implications in localizing these proteins to important signalling complexes.
Methods

Materials
Materials (chemicals and vendors) are given in Supplementary material online.
Proteins and antibodies
Glutathione-S-transferase (GST)-coupled full-length MYPT1 (GST-MYPT1 ) and a C-terminal fragment (GST-MYPT1 667-1004 ) 8 or hexahistidine (His)-tagged N-terminal MYPT1 fragments (His-MYPT1 1-633 , His-MYPT1 1-296 , His-MYPT1 304-511 ) 20 were expressed in Escherichia coli and purified as described. PP1c and PP2Ac were purified from rabbit skeletal muscle. 21 CN was purified from bovine brain. 22 The antibodies and immunochemicals used are detailed in Supplementary material online. 
Cell cultures, treatments, and transfections
Immunoblotting
Proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS -PAGE) on 10 -20% acrylamide gels and blotted onto nitrocellulose membranes 23 which were exposed to the antibodies and analysed as given in Supplementary material online.
Pull-down assays
GST-MYPT1 pull-down from BPAEC lysates were performed as described previously. 24 Cells of tsA201 were transfected with Flag-peptide (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys)-coupled MYPT1 (Flag-MYPT1) or co-transfected with Flag-MYPT1 plus CN-Aa/pEGFP plasmids. Flag-MYPT1 as well as its associated proteins were isolated from cell lysates on anti-Flag resin according to the manufacturer's recommendations. Resin-bound proteins were solubilized by boiling in SDS sample buffer and were subjected to western blotting using anti-MYPT1 25 Phosphatase assays were accomplished as given in Supplementary material online.
Surface plasmon resonance
Interaction of MYPT1 with CN was analysed by SPR using a Biacore 3000 instrument. GST-and His-tagged MYPT1 proteins were immobilized on CM5 sensor chips and determination of the binding of CN or PP1c on these surfaces was performed as described. 23 Kinetic parameters and the association constant (K a ) values were extracted from the sensograms using the BIAevaluation 3.1 software.
Measurement of transendothelial electrical resistance
Transendothelial electrical resistance (TER) was measured dynamically across a confluent monolayer of BPAECs, using an electrical cell-substrate impedance sensing system (Applied Biophysics, Troy, NY, USA) as described previously. 26 Decreases in monolayer resistance to electrical current flow, which correlated with paracellular gap formation, were measured according to the method described. 27 
Immunofluorescence and confocal microscopy
BPAECs and HPAECs were prepared for immunofluorescence as described 19 and were imaged on an Olympus Fluoview 1000 confocal microscope (Hamburg, Germany) using a 60× UPLSAPO (NA 1.35) oil Regulation of myosin phosphatase by calcineurin immersion objective. Pearson's correlation coefficients were determined as described. 28 
Statistical analysis
Statistical significance of differences in measured variables between control and treated samples was determined by Student's t-test or one-way ANOVA. Difference was considered significant at P , 0.05 and indicated as *P , 0.05, **P , 0.01, or ***P , 0.001.
Results
CN dephosphorylates MYPT1 in endothelial and tsA201 cells
Pharmacological inhibition of CN by CsA in cultured BPAECs ( Figure 1A ) or HPAECs ( Figure 1B ) resulted in a marked increase ( 3.5 and 2.1-fold, respectively) in MYPT1 pThr696 , indicating that CN was involved in the dephosphorylation of this residue. H1152, a specific ROK inhibitor, inhibited the CsA-induced increase in MYPT1 pThr696
, suggesting the role of ROK in the phosphorylation process. CsA also increased MYPT1
pThr853 , but to a somewhat smaller extent than that of MYPT1 pThr696 in both BPAECs and
HPAECs (see Supplementary material online, Figure S1A and B) also in an ROK-dependent manner. Changes in endogenous MYPT1 pThr696 were also determined ( Figure 1C ) in tsA201 cells transfected with a plasmid coding for a pEGFP-coupled constitutively active CN-A form, in which the CaM-binding and autoinhibitory domains were truncated (DCN-A/pEGFP). 19 The per cent changes in MYPT1 pThr696
were estimated by densitometry of western blots and untransfected cells served as a control (100%). After overexpression of DCN-A/ pEGFP or pEGFP alone, MYPT1 pThr696 levels were 49 + 9 and 142 + 41% (n ¼ 3) compared with control, respectively, implying again the role of CN in MYPT1 dephosphorylation. In in vitro phosphatase assays, purified CN dephosphorylated recombinant GST-MYPT1 substrate ( 32 P-labelled at Thr696 and Thr853 via phosphorylation by ROK) in a dose-and Ca 2+ -CaM-dependent manner ( Figure 1D ). Figure 2C and D) in both BPAECs and HPAECs. An apparent increase in the F-actin content of HPAECs was also seen by fluorescent microscopy (see Supplementary material online, Figure S3 ), highlighting another consequence of CN inhibition in ECs. The necessity of elevated [Ca 2+ ] i to increase MYPT1 pThr696 was also assessed in BPAECs. In the absence of intracellular Ca 2+ , CsA had no effect on the level of MYPT1 pThr696 ( Figure 2E ).
Interaction of MYPT1 with CN as revealed by pull-down, coexpression, and colocalization experiments
Pull-down experiments with Flag-MYPT1 and GST-MYPT1 in tsA201 and EC lysates containing endogenous CN were carried out to analyse the physiological relevance of MYPT1 and CN interaction. CN-Aa ( Figure 3A , left panel, and see Supplementary material online, Figure S2A ) and PP1cd ( Figure 3A , left) were identified as Flag-MYPT1 interacting proteins in tsA201 cells as judged by western blots. When both Flag-MYPT1 and CN-Aa/pEGFP were coexpressed in tsA201 cells, the coprecipitation of these proteins was also observed (see Supplementary material online, Figure S2B ). Flag-MYPT1 isolated from tsA201 cells on anti-Flag resin (and freed of associated proteins) pulled down CN-Aa and PP1cd from both BPAEC and HPAEC lysates Regulation of myosin phosphatase by calcineurin ( Figure 3 , middle and right panels), implicating that the interaction of MYPT1 and CN occurred at the cellular level and it was not obstructed by PP1c bound to MYPT1. Non-phosphorylated GST-MYPT1 pulled down the CN-Aa subunit from EC lysate (see Supplementary material online, Figure S2C ), indicating that phosphorylation of MYPT1 is not necessary to the interaction. Confocal microscopy localized both CN-Aa and MYPT1 predominantly in the cytoplasm and to a lesser extent in the nucleus in BPAECs ( Figure 3B , left panels) and HPAECs ( Figure 3B , right panels). The appearance of merged images suggested colocalization of these proteins in both cell types, which was confirmed by the determination of the Pearson's correlation coefficients (see C-values in legend to Figure 3B ). Thrombin treatment induced shape change and formation of gaps between the cells; however, it did not alter the extent and pattern of the colocalization of MYPT1 and CN.
Interaction of MYPT1 and CN assessed by SPR-based binding experiments
To clarify the molecular background for the formation of the CN-MYPT1 complex, binding of CN to full-length and truncated mutants of MYPT1 was determined in SPR-based experiments using purified proteins. Figure 4A shows that CN bound to the full-length GST-MYPT1 surface in a concentration range of 1-5 mM. Assuming the formation of a 1:1 complex, an association constant of K a ¼ (1.86 + 1.37) × 10 7 M 21 was derived from the binding curves.
In contrast, CN hardly bound to the GST-MYPT1 667-1004 surface, resulting in only slight and 'noisy' increase of the resonance signals even at higher, 5 -10 mM CN concentrations ( Figure 4B) , implying that the C-terminal region of MYPT1 is not a major determinant in the interaction. In contrast, the mutant representing the N-terminal half of MYPT1 (His-MYPT1 ) similar to that of the full-length MYPT1 1-1004 ( Figure 4C) . However, the association and dissociation kinetics appeared to be distinct, which may indicate different availability of the binding sites in these two proteins and/or reflect differences in the immobilization techniques. The binding of CN to His-MYPT1 1-296 ( Figure 4D ) or His-MYPT1 304-511 ( Figure 4E) Possible competition between PP1c and CN was assessed since PP1c was also shown to bind to the N-terminal MYPT1 region. Figure 4F shows that the response U obtained by injecting PP1c or CN alone until saturation were added up when the two proteins were applied in combination. Furthermore, CN was able to bind to the MYPT1 surface saturated with PP1c ( Figure 4G) , confirming that the binding of PP1c and CN to MYPT1 was not mutually exclusive.
Inhibition of CN by CsA sustains MYPT1 and myosin phosphorylation upon thrombin treatment accompanied by increased endothelial permeability
It was established that during thrombin treatment of ECs, transient phosphorylation of MLC20 occurs, which is coupled with transient inactivation of MP. 30 Changes in MYPT1 Thr696 following thrombin stimulation were also transient, peaking at 1 min and declining approximately to the initial level at 10 min ( Figure 5A ). In contrast, when BPAECs were pretreated with CsA there was a marked increase in MYPT1 pThr696 before the addition of thrombin. This MYPT1 pThr696 level decreased significantly (to 75% of the maximal value) upon the addition of thrombin, but it still remained sustained at this relatively high level ( Figure 5A , middle and lower panel). The most prominent difference between MYPT1 pThr696 levels measured in the absence and presence of CsA upon the addition of thrombin was observed at 10 min. Therefore, we assessed phosphorylated MLC20-Ser19 (MLC20 pSer19 ) in BPAECs in the absence and presence of CsA after 10 min after thrombin treatment. CsA or thrombin alone slightly increased MLC20 pSer19 , whereas a more significant increase occurred when thrombin was applied after CsA pretreatment ( Figure 5B) . Similar patterns were observed in the changes of MLC20 pSer19 in BPAECs by fluorescent staining ( Figure 5C , left panel) following the above treatments. Quantification of MLC20 pSer19 in the fluorescently labelled samples of BPAECs by flow cytometry analysis ( Figure 5D ) was reminiscent of the changes obtained by the densitometry of western blots ( Figure 5B) . The appearance of actin filaments was also altered ( Figure 5C , middle panel). In the presence of CsA or thrombin, the shape of the cells changed and the amount of the stress fibres increased, whereas the combined application of CsA and thrombin resulted in the local enrichment of MLC20 pSer19 and its colocalization with the cortical actin filaments. Changes in the phosphorylation level of myosin are often reflected in altered endothelial barrier function. TER of BPAEC monolayers was determined by applying the same treatments as in the cell-based assays of MYPT1 and MLC20 phosphorylation. Figure 6A shows that CsA caused a rapid, significant decrease of TER for a prolonged 
GST-MYPT1
667-1004 C-terminal fragment (B) and His-MYPT1 1-633 (C), His-MYPT1 1-296 (D), and His-MYPT1 304-511 (E) N-terminal fragments were immobilized on CM5 chips coupled with anti-GST (A, B, F, and G) or via direct amine coupling (C, D, and E). CN (A -G) or PP1cd (F and G), or PP1c plus CN (F and G) was injected over the surfaces at concentrations indicated on the sensograms. Sensograms were obtained using Biacore 3000. Representative sensograms of two to three independent experiments with similar results are shown.
Regulation of myosin phosphatase by calcineurin period ( 2 h) before recovery. Thrombin alone induced also a fast and more pronounced decrease in TER than did CsA; however, the recovery appeared to be faster and completed in 45 min. Pretreatment of BPAECs with CsA before thrombin addition did not alter the extent of decrease in TER induced by thrombin; however, a sustained decrease in TER ( 1.5 h) was observed, suggesting that CsA slowed down significantly the recovery of TER. The changes in TER of BPAECs reflect alterations in endothelial permeability paralleling in part the changes in MLC20 pSer19 observed under the same conditions.
Discussion
Our present work identifies CN as an MYPT1 phosphatase acting directly, and in a Ca 2+ -CaM manner, on the PP1c inhibitory MYPT1 pThr696 site. Dephosphorylation of MYPT1 by CN has been shown previously; however, its physiological relevance was doubted since cell lysates did not exhibit any Ca 2+ -CaM dependent activity assayed with phospho-MYPT1 substrate. 16 We provide evidence here for the direct interaction of CN with MYPT1, and the occurrence of the dephosphorylation of MYPT1 by CN at cellular level It was shown that CN inhibitors (CsA, FK506, deltamethrin) influence EC permeability. FK506 alone did not alter TER, but it prevented the reversal of thrombin-induced decrease in resistance, whereas PP1 and PP2A inhibitors were without effect. 18 The effect of FK506 was attributed to a CN-inhibition-dependent increase in the phosphorylation of protein kinase Ca. Inhibition of CN by deltamethrin also increased endothelial permeability and it was due to enhanced MLC20 phosphorylation. 17 Our results suggest that CN inhibition by CsA decreases TER in BPAECs to a significant extent without a profound change in MLC20 phosphorylation. We hypothesize that this change in TER by CsA is due to an increase in cofilin pSer3 , resulting in enhanced actin polymerization with subsequent alterations in EC cell shape and permeability. CsA treatment also slows down the recovery of decreased TER induced by thrombin and this effect appears to parallel the sustained level of MYPT1 pThr696 and MLC20 pSer19 . Our data imply that CN inhibition by CsA exerts both MLC20 phosphorylation-dependent and independent effects. Our finding that CN forms a stable complex with dephosphorylated MYPT1 indicates that the interaction between these two proteins is stronger than it would be expected for a simple enzyme-phosphosubstrate adduct. SPR-binding studies establish the essential role of the N-terminal region of MYPT1 in the interaction with CN. Accordingly, there is a CN-substrate-docking PxIxIT-like motif 33 ) than that of the mutant representing the N-terminal half (MYPT1 ) or the fulllength (MYPT1 ) protein (K a ≈ 10 7 ). Nevertheless, MYPT1 for PP1c and CN could also be excluded as the two proteins coprecipitate with Flag-MYPT1 during pull-downs and bind independently to MYPT1 surface in SPR binding studies, suggesting that CN presumably interacts with the MP holoenzyme with the same affinity as does with MYPT1. In summary, we identified a mechanism of how CN may modulate the phosphorylation level of MLC20 in myosin via influencing the phosphorylation state of a PP1c inhibitory site in the MYPT1 subunit of MP. It is assumed that these CN-induced changes of the phosphorylation status of MLC20 and MYPT1 are also reflected in the contractile features of ECs and in the alterations of barrier function. The relatively strong interaction formed between CN and MYPT1 (and the MP holoenzyme) may have broader physiological significance in localizing these enzymes close to their possible substrates forming functionally important signalling complexes.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
